Ignite Creation Date:
2025-12-25 @ 2:00 AM
Ignite Modification Date:
2026-03-07 @ 10:44 PM
Study NCT ID:
NCT02805660
Status:
TERMINATED
Last Update Posted:
2021-04-06
First Post:
2016-06-10
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC
Sponsor:
Mirati Therapeutics Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
0103-020
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None